Levels of Inflammation in Middle East People With Cardiovascular Disease With/Without Kidney Disease

CompletedOBSERVATIONAL
Enrollment

756

Participants

Timeline

Start Date

November 22, 2024

Primary Completion Date

August 28, 2025

Study Completion Date

August 28, 2025

Conditions
Systemic Inflammation (hsCRP)
Interventions
OTHER

No treatment given

Participants will continue their normal care and will not get any treatment as part of this study.

Trial Locations (20)

4545

Rashid Hospital, Dubai

7272

Dubai Hospital, Dubai

12214

Dr. Sulaiman Al Habib Medical Group- Olaya, Riyadh

12345

Fujairah Hospital, Al Fujairah City

Sheikh Khalifa Hospital Fujairah, Al Fujairah City

Al Qassimi Hospital, Sharjah, Sharjah city

12372

King Khaled University Hospital,King Saud Univ. Med. City, Riyadh

12381

Dallah Hospital_Riyadh, Riyadh

12713

King Faisal Specialist Hospital & Research Centre, Riyadh, Riyadh

13215

SMC, Riyadh, Riyadh

15258

Tawam Hospital (SEHA), Abu Dhabhi

23311

King Fahad Armed Forces, Jeddah, Jeddah

23433

King Faisal Specialist Hospital & Research Centre, Jeddah, Jeddah

36342

Almoosa Specialist Hospital, Al Ahsa

46713

Mediclinic Abu Dhabi, Abu Dhabhi

47512

King Salman North Western Armed Force Hospital (NWAFH), Tabuk

48338

Imperial college, Abu Dhabi, Abu Dhabhi

59046

King Fahad Medical City, Riyadh

112412

Cleveland Clinic Abu Dhabi, Abu Dhabhi

123456

Tadwai hospital, Dubai

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY